MEN1 is a familial tumour syndrome that is inherited in an autosomal dominant manner caused by a germline mutation in the MEN1 gene. It includes varying combinations of endocrine and nonendocrine neoplasms. MEN1 is diagnosed on a clinical basis, when a patient is found to have two of the three main MEN1-related endocrine tumours (parathyroid adenomas, entero-pancreatic endocrine tumours, and pituitary tumour); on a familial basis, when a patient has one MEN1-associated tumour and an affected first-degree relative; and finally on a genetic basis, when an individual has an MEN1 pathogenic mutation. 3, 4 Other neoplasms associated with MEN1 include neuroendocrine and adrenocortical tumours, facial angiofibromas, collagenomas, lipomas, meningiomas, ependymomas and leiomyomas. 3, 5 The prevalence of pituitary tumours in MEN1 varies widely from 10% to 60%, with pituitary tumours presenting as the first clinical manifestation of MEN1 in 25% of sporadic and 10% of familial cases. 6, 7 ACTH-secreting tumours are generally rare in MEN1, representing only approximately 2% of cases. 4 The literature on patients with MEN1 over the age of 18 years includes a limited number of cohorts with CS. [8] [9] [10] In this report, we describe a cohort of six paediatric patients who presented with CD as their first manifestation of MEN1. Three patients from our cohort had been previously included in papers published from our institution by Simmonds et al 8 and Stratakis et al. 11 The present report aims to expand the cohort of MEN1 patients presenting with CD to include more recently discovered cases as well as patients found to have MEN1 through novel methods of testing, including whole exome sequencing.
| MATERIAL S AND ME THODS

| Clinical studies on CS and CD
We performed a retrospective chart review of paediatric patients (<21 years at diagnosis) admitted to our institution for evaluation of hypercortisolism between 1997 and 2017 and recruited under the research protocol 97-CH-0076 of the Eunice Kennedy Shriver National 
| RE SULTS
| Patients
Of a total of 238 patients with CD evaluated at our institution since 1997, we identified 6 patients with an additional diagnosis of MEN1
at the time of their discharge after the initial evaluation of hypercortisolism. Our cohort included three males and three females with a mean age at diagnosis of 13.4 ± 2.9 years old ( Table 1 ). The most common presenting symptoms included weight gain and poor growth, similar to that of all our other patients with CD occurring sporadically (Table 1) . Follow-up evaluation was carried out at 6 months and 1 year after the surgery. One patient was lost to follow-up (patient 3).
For two cases (patients 4 and 5), longer follow-up evaluations were available at 6-7 years after their initial inpatient admission.
All the six patients had elevated UFC in at least three urine samples prior to their evaluation at the NIH. Four of six patients (patients 1-3,6) had documented elevated midnight serum cortisol levels (>4.4 μg/dL) and a positive response to HDDST ( Table 2 ). The two patients to whom diurnal serum cortisol measurements were not indicative of CS (patient 4 and 5, Table 2 
| Evaluation for MEN1
Five of six patients included in our cohort had a strong family A dermatology evaluation showed that one patient (patient 1)
had nasal angiofibromas consistent with MEN1, whereas another (patient 5) had possible face angiofibromas in the setting of acne vulgaris, that were unable to differentiate from acneiform lesions.
Additional screening imaging for MEN1 related disease, had revealed a stable asymptomatic pancreatic mass in patient 5, which is followed regularly by abdominal scans.
| Genetic and DNA studies
Germline MEN1 mutational testing results were available for all the patients included in our cohort (Table 3) . Five of six patients had familial MEN1 that was identified either at the time of the first interview or after genetic testing became available. One patient was a de novo MEN1 case (patient 6). The MEN1 gene was sequenced;
if there were no mutations, deletion testing was performed. MEN1 mutational testing was only performed in patients when there was suggestive family history and/or other manifestations on presentation (eg hypercalcemia or hyperprolactinemia found on routine testing). The remaining patients from our cohort of 238 patients did not have MEN1 DNA testing thus our cohort may include a few more undiagnosed cases of MEN1 that were not sequenced for.
| Clinical outcome and follow-up
All the patients included in our cohort were cured with resolution of their CS-associated symptoms, including one patient with spontaneous resolution of symptoms s/p likely pituitary apoplexy. Serum cortisol levels were normalised in all patients, both in the immediate post-op period as well as their follow-up visit (apart from patient 3 who never returned for follow-up). Biochemical remission was defined as midnight cortisol <4.4 μg/dL or urinary free cortisol levels within the normal range at the first follow-up visit at 6-12 months post-TSS.
Two patients developed post-op panhypopituitarism (patients 4 and 6). The remaining patients for whom follow-up data were avail- which she is now on hormone replacements as clinically indicated.
Patient 6 was only recently evaluated at our institution and at her 8-month follow-up visit after surgery, the midnight cortisol levels were <1 μg/dL and her hyperprolactinemia had also resolved. However, she was found to have low plasma IGF-1 levels, low free thyroxine 
| D ISCUSS I ON
This report describes a cohort of paediatric patients with MEN1 in whom CD was the initial clue exhibiting the presence of the syndrome. MEN1 is an autosomal dominant familial cancer syndrome with high penetrance. Manifestations can initiate as early as 5 years of age and it is estimated that 95% of the patients will develop tumours by the fifth decade of life. 3 The most common tumours found in MEN1 patients are tumours of the parathyroid glands (85%). For patients who do not present with primary hyperparathyroidism, the most common initial manifestation is a gastrinoma or prolactinoma. who was found to have a germline de novo MEN1 mutation as part of genetic MEN1 screening (patient 4 in the article published by Karageorgiadis et al. 14 Simonds et al 8 recently described 19 adult MEN1 patients with CS; 79% had CD and 21% had ACTHindependent CS.
In our case series, none of the patients was previously diagnosed with MEN1 despite the fact that in most cases there was a strong family history suggestive of MEN1-related tumours. While published guidelines recommend screening first degree relatives of MEN1 patients, this was not the case in the patients included in this cohort. What is unique in these patients is that CD was the initial manifestation of MEN1. As Stratakis et al 11 previously suggested the present study confirms that in a small number of paediatric patients with CD, an ACTH-producing adenoma may be the first manifestation of MEN1. Although a rare finding in patients with CS, the diagnosis of an underlying familial cancer syndrome is of paramount importance for the prognosis and long-term surveillance of these patients, and it behoves clinicians that diagnose children with CD to inquire carefully on family history suggestive of MEN1 and if suspected, MEN1 gene and deletion testing should be pursued.
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